Grants awarded through the Cross-Species Studies of ASD RFA were intended to support multi-disciplinary teams of PIs with expertise in both human and animal research to perform coordinated cross-species studies to advance our understanding of ASD-relevant behaviors and their underlying neurobiological mechanisms, with the potential for developing novel biomarkers or interventions.

The Human Cognitive and Behavioral Science RFA prioritized research that produces foundational knowledge about the neurobehavioral differences associated with ASD. These projects were expected to inform or relate to the development and refinement of tools needed for translational efforts, such as biomarkers and outcome measures. Special emphasis was placed on objective, quantitative measures that may be used in conjunction with standardized clinical measures and genomic information to better characterize phenotypic and neurobiological variability within and across individuals with ASD.

Grants awarded through this RFA were intended to improve our understanding of the molecular and cellular consequences of genetic risk for ASD, and to provide a foundation for the development of new therapies. Special emphasis was placed on the use of scalable methods, especially as applied to genes that are suitable targets for genetic therapies.

Grants awarded through this RFA were intended to advance the understanding of autism spectrum disorder through analyses of human postmortem brain tissue donated to the Autism BrainNet collection.

SFARI launched the Autism Rat Models Consortium (ARC) in 2022 with a group of researchers funded through the original Autism Rat Models Consortium RFA. These researchers are using rats generated with SFARI funding that carry mutations in high-confidence genes that in humans significantly increase the likelihood of developing autism and related NDD. As part of the consortium, these same rat models are being evaluated through a comprehensive behavioral phenotyping pipeline established by the Simons Initiative for the Developing Brain (SIDB).

Grants awarded through this RFA supplemented funding from other agencies for ongoing pregnancy cohorts to broaden biospecimen collection and to extend post-natal family tracking. These cohorts and biospecimen collections can be leveraged in future research to understand the effects of gestational infection and inflammation on autism risk in children.

SFARI Collaborations are a new funding mechanism that will provide substantive and stable funding support to multidisciplinary teams of investigators tackling critical issues in the autism research field. Collaborations will be led by a director who oversees interdisciplinary, synergistic research efforts across multiple laboratories. Investigative groups within a Collaboration will focus on the same conceptually unified topic but will incorporate different scientific disciplines, multiple levels of analysis, and will include a robust data-sharing infrastructure.
 
SFARI Collaborations have a maximum budget of up to $8,000,000, including 20 percent indirect costs, over an initial period of four years, with a possible three-year extension.
 
For our first Collaboration RFA, SFARI solicits applications to investigate sex differences in autism.

Grants awarded through this RFA were intended to provide support for the investigation of key unresolved research questions in autism, particularly those that connect etiology to brain function and behavior. SFARI welcomed risk and novelty in Research Award proposals, but potential impact on the autism research field was the most important criterion. Competitive applications had preliminary data or other relevant groundwork that justifies substantial investment on the proposed topic.

Grants awarded through this RFA were intended to develop and validate outcome measures that are suitable for use in intervention studies that target the core symptoms of autism spectrum disorder. Such measures should provide objective data with strong psychometric properties, be scalable for use in large, multisite studies, not be unduly burdensome to participants and families, and have evident clinical relevance. They would ideally capture naturalistic rather than laboratory behavior and be applicable to subjects across a wide range of ages and levels of functioning.

SPARK is a SFARI initiative intended to recruit, engage and retain a community of 50,000 individuals with autism, and their family members, in the United States. This research cohort includes children and adults who span the full autism spectrum and individuals of all socio-demographic backgrounds. Through this RFA, SFARI supported additional U.S.-based clinical sites for the purpose of recruiting individuals with ASD and their family members to participate in SPARK.